A Baseline Risk Factors	Total No.	Placebo + Erlotinib (n = 249)			Onartuzumab + Erlotinib (n = 250)							
		No.	Events	Median (months)	No.	Events	Median (months)	HR	95% CI			
All patients	499	249	204	2.6	250	210	2.7	1.01	0.83 to 1.22			
BRAF mutation												
Detected Not detected	311	3 149	3 120	1.3 2.0	162	137	2.4 2.7	1.73 1.04	0.23 to 12.78 0.81 to 1.33		-	_
EGFR mutation	20	12	2	NE		3		4.53				
Detected No call	20 50	12 20	16	NE 2.7	8 30	25	NE 1.7	1.57	0.31 to 7.90 0.66 to 2.38			-
Not detected	246	120	104	1.4	126	111	2.7	0.94	0.72 to 1.23	i	Ε.	
KRAS mutation												
Detected	88	42	38	1.4	46	41	3.1	0.67	0.43 to 1.05	-	1	
No call Not detected	15 213	103	6 79	1.9 2.8	110	8 90	1.3	2.58 1.13	0.82 to 8.08 0.83 to 1.52			-
PIK3CA mutation	213	100	7.0	2.0	110	30	2	1.10	0.03 10 1.02		Г	
Detected	15	7	4	4.1	8	7	3.4	1.88	0.55 to 6.45		_	4
No call	36	17	13	3.7	19	16	1.6	1.75	0.81 to 3.79		-	
Not detected	265	128	106	1.4	137	116	2.7	0.96	0.73 to 1.24		۴	
MET gene amplification	0.5		00		00	23	4.0	1,47	0.86 to 2.51		L.,	
Amplified Other	65 91	39 46	36 36	1.4	26 45	23 35	1.3	1.47 0.94	0.86 to 2.51 0.59 to 1.49		F	
EGFR gene amplification				2.10		55	2.0	0.04	2.00 10 1.40			
Amplified	41	23	20	2.8	18	14	1.6	1.46	0.70 to 3.03		-	
Other	242	116	90	2.7	126	103	2.8	1.01	0.76 to 1.35		þ.	
MET FISH												
Positive	156 315	85 150	72 118	1.5	71 165	58 141	2.7	1.07	0.75 to 1.51		t .	
Negative	315	150	118	2.7	105	141	2.7	1.02	0.80 to 1.30		r	
EGFR FISH Positive	280	137	109	2.7	143	116	2.8	1.02	0.79 to 1.33		L.	
Negative	191	98	81	2.2	93	83	2.6	1.04	0.77 to 1.42		ī.	
		Die	saaba - Er	dosinih	0		. Calorinib			avors onartuzumab + orlotinib		
В		Pla	scebo + Er (n = 24)	lotinib 9)	Onar	rtuzumab (n = 25	e Erlotinib			nartuzumab +		placebo
<b>B</b> Baseline Risk Factors	Total No.	Pla No.	{n = 24	lotinib 9) Median (months)	Onar No.	(n = 25	+ Erlotinib i0) Median (months)	HR		nartuzumab +		placebo
Baseline Risk Factors		_	{n = 24	9) Median	_	(n = 25	i0) Median	HR 1.27	95% CI	onartuzumab + erlotinib		placebo
Baseline Risk Factors All patients	No.	No.	(n = 24) Events	Median (months)	No.	(n = 25 Events	Median (months)		e	onartuzumab + erlotinib		placebo
Baseline Risk Factors All patients BRAF mutation Detected	No. 499 5	No. 249	(n = 24) Events 114	Median (months) 9.1 NE	No. 250	(n = 25 Events 130	Median (months) 6.8	1.27	95% CI 0.98 to 1.63	onartuzumab + erlotinib		placebo
Baseline Risk Factors All patients BRAF mutation Detected Not detected	No. 499	No. 249	(n = 24) Events 114	Median (months)	No. 250	(n = 25 Events 130	Median (months) 6.8	1.27	95% CI 0.98 to 1.63	onartuzumab + erlotinib		placebo
Baseline Risk Factors  All patients  BRAF mutation Detected Not detected  EGFR mutation	No. 499 5 331	No. 249 3 149	Events 114 1 68	Median (months) 9.1 NE 9.1	No. 250 2 162	(n = 25 Events 130 1 92	Median (months) 6.8 NE 6.5	1.27 > 999.99 1.39	95% CI 0.98 to 1.63 0.0 to NE 1.01 to 1.90	onartuzumab + erlotinib		placebo
Baseline Risk Factors All patients BRAF mutation Detected Not detected	No. 499 5	No. 249	(n = 24) Events 114	Median (months) 9.1 NE	No. 250	(n = 25 Events 130	Median (months) 6.8 NE 6.5	1.27	95% CI 0.98 to 1.63	onartuzumab + erlotinib		placebo
Baseline Risk Factors  All patients  BRAF mutation  Detected  Not detected  EEFR mutation  Detected	No. 499 5 331 20	No. 249 3 149	Events 114 1 68	Median (months) 9.1 NE 9.1	No. 250 2 162 8	(n = 25 Events 130 1 92	Median (months) 6.8 NE 6.5	1.27 > 999.99 1.39 2.92	95% CI 0.98 to 1.63 0.0 to NE 1.01 to 1.90	nartuzumab + erlotinib		placebo
Baseline Risk Factors  All patients  BRAF mutation Detected Not detected  EGFR mutation Detected No call Not detected	No. 499 5 331 20 50 246	No. 249 3 149 12 20 120	In = 248 Events 114 1 68 1 10 58	9) Median (months) 9.1 NE 9.1 NE 7.8	No. 250 2 162 8 30 126	(n = 25 Events 130 1 92 2 18 73	Median (months) 6.8 NE 6.5 12.6 5.6 6.4	1.27 > 999.99 1.39 2.92 1.42 1.34	95% CI 0.98 to 1.63 0.0 to NE 1.01 to 1.90 0.26 to 32.93 0.64 to 3.19 0.95 to 1.89	nartuzumab + ortotinib		placebo
Baseline Risk Factors  All patients  BRAF mutation  Detected  Not detected  EGFR mutation  Detected  No call  Not detected  KRAS mutation  Detected  CRAS mutation	No. 499 5 331 20 50 246 88	No. 249 3 149 12 20 120 42	(n = 24) Events 114 1 68 1 10 58 19	9) Median (months) 9.1 NE 9.1 NE 6.5 7.8 NE	No. 250 2 162 8 30 126 46	(n = 25 Events 130 1 92 2 18 73 26	Median (months) 6.8 NE 6.5 12.6 5.6 6.4 8.8	1.27 > 999.99 1.39 2.92 1.42 1.34 0.95	95% CI  0.98 to 1.63  0.0 to NE 1.01 to 1.90  0.26 to 32.93 0.64 to 3.19 0.95 to 1.89	anartuzumab + ortotinib	I a . I	placebo
Baseline Risk Factors  All patients  BRAF mutation Detected Not detected  EGFR mutation Detected No call Not detected	No. 499 5 331 20 50 246	No. 249 3 149 12 20 120	In = 248 Events 114 1 68 1 10 58	9) Median (months) 9.1 NE 9.1 NE 7.8	No. 250 2 162 8 30 126	(n = 25 Events 130 1 92 2 18 73	Median (months) 6.8 NE 6.5 12.6 5.6 6.4	1.27 > 999.99 1.39 2.92 1.42 1.34	95% CI  0.98 to 1.63  0.0 to NE 1.01 to 1.90  0.26 to 32.90  0.95 to 1.89  0.52 to 1.74  0.51 to 8.49	anartuzumab + ortotinib		placebo
Baseline Risk Factors  All patients  8RAF mutation Detected Not detected Detected No call Not detected No call Detected Not detected No Not detected Not detected Not detected Not detected No Not detected No call	No. 499 5 331 20 50 246 88 15	No. 249 3 149 12 20 120 42 7	Events  114  1 68  1 10 58  19 4	9)  Median (months)  9.1  NE 9.1  NE 6.5 7.8  NE 5.1	No. 250 2 162 8 30 126 46 8	(n = 25 Events 130 1 92 2 18 73 26 6	Median (months) 6.8 NE 6.5 12.6 5.6 6.4 8.8 4.6	1.27 > 999.99 1.39 2.92 1.42 1.34 0.95 2.08	95% CI  0.98 to 1.63  0.0 to NE 1.01 to 1.90  0.26 to 32.93 0.64 to 3.19 0.95 to 1.89	anartuzumab + ortotinib		placebo
Baseline Risk Factors  All patients  8RAF mutation Detected Not detected No call Not detected No call Detected No to detected No to detected Not detected Not detected No Risk Mutation Detected No call Detected Detected Detected Detected Detected	No. 499 5 331 20 50 246 88 15 213	No. 249 3 149 12 20 120 42 7 103	In = 24: Events 114 1 68 1 10 58 19 4 46 1	9) Median (months) 9.1 NE 9.1 NE 6.5 7.8 NE 5.1 9.1	No. 250 2 162 8 30 126 46 8 110	(n = 25 Events 130 1 92 18 73 26 6 61	Median (months) 6.8 NE 6.5 12.6 5.6 6.4 8.8 4.6 6.3	1.27 > 999.99 1.39 2.92 1.42 1.34 0.95 2.08 1.63 3.73	95% CI  0.98 to 1.63  0.0 to NE 1.01 to 1.90  0.26 to 32.93  0.84 to 3.18  0.52 to 1.74  0.51 to 8.49  1.11 to 2.39  0.39 to 36.00	anartuzumab + priotinib		placebo
Baseline Risk Factors  All patients  BRAF mutation Detected  Not denoted GEFF mutation Detected  Detected  Not destected  Not all  Not destected  Not all  Not destected	No. 499 5 331 20 50 246 88 15 213 15 36	No. 249 3 149 12 20 120 42 7 103	In = 24: Events  114  1 68  1 10 58  19 4 46  1 7	9) Median (months)  9.1  NE 9.1  NE 6.5 7.8  NE 5.1  9.1	No. 250 2 162 8 30 126 46 8 110 8 19	(n = 25 Events 130 1 92 2 18 73 26 61 4	Median (months) 6.8 NE 6.5 12.6 5.6 6.4 8.8 4.6 6.3 5.0 3.3	1.27 > 999.99 1.39 2.92 1.42 1.34 0.95 2.08 1.63 3.73 2.25	95% CI 0.98 to 1.63 0.0 to NE 1.01 to 1.90 0.26 to 32.90 0.84 to 3.19 0.52 to 1.74 0.51 to 8.49 1.11 to 2.39 0.39 to 36.00 0.94 to 6.03	anartuzumab + priotinib		placebo
Baseline Risk Factors  All patients  RRAF mutation Detected  Not detected  No tothetected  Not detected  Not detected	No. 499 5 331 20 50 246 88 15 213	No. 249 3 149 12 20 120 42 7 103	In = 24: Events 114 1 68 1 10 58 19 4 46 1	9) Median (months) 9.1 NE 9.1 NE 6.5 7.8 NE 5.1 9.1	No. 250 2 162 8 30 126 46 8 110	(n = 25 Events 130 1 92 18 73 26 6 61	Median (months) 6.8 NE 6.5 12.6 5.6 6.4 8.8 4.6 6.3	1.27 > 999.99 1.39 2.92 1.42 1.34 0.95 2.08 1.63 3.73	95% CI  0.98 to 1.63  0.0 to NE 1.01 to 1.90  0.26 to 32.93  0.84 to 3.18  0.52 to 1.74  0.51 to 8.49  1.11 to 2.39  0.39 to 36.00	anartuzumab + priotinib		placebo
Baseline Risk Factors  All patients  BRAF mutation Detected Not detected EGFF mutation Detected Not detected Not detected Not Authority Not detected No call Not detected No call Detected No call Detected No call Motification Detected Not detected	No. 499 5 331 20 50 246 88 15 213 15 36 265	No. 249 3 149 12 20 120 42 7 103 7 17 128	Events 114 1 68 1 10 58 19 4 466 1 7 61	9) Median (months) 9.1 NE 9.1 NE 6.5 7.8 NE 5.1 9.1 NE 7.4 9.1	No. 250 2 162 8 30 126 46 8 110 8 19	(n = 25 Events 130 1 92 2 18 73 26 6 6 61 4 12 77	Median (months) 6.8 NE 6.5 12.6 5.6 6.4 8.8 4.6 6.3 5.0 3.3 6.5	1.27 > 999.99 1.39 2.92 1.42 1.34 0.95 2.08 1.63 3.73 2.26 1.33	95% CI 0.98 to 1.63 0.0 to NE 1.01 to 1.30 0.26 to 32.93 0.94 to 3.19 0.52 to 1.74 0.51 to 8.49 1.11 to 2.39 0.39 to 36.03 0.95 to 1.38	nantzumab + rirotinib		placebo
Baseline Risk Factors All patients 8RAF mutation Detected Not detected SefF mutation Detected Not detected No call Not detected No call Not detected No call Not detected No call	No. 499 5 331 20 50 246 88 15 213 15 36	No. 249 3 149 12 20 120 42 7 103	In = 24: Events  114  1 68  1 10 58  19 4 46  1 7	9) Median (months)  9.1  NE 9.1  NE 6.5 7.8  NE 5.1  9.1	No. 250 2 162 8 30 126 46 8 110 8 19	(n = 25 Events 130 1 92 2 18 73 26 61 4	Median (months) 6.8 NE 6.5 12.6 5.6 6.4 8.8 4.6 6.3 5.0 3.3	1.27 > 999.99 1.39 2.92 1.42 1.34 0.95 2.08 1.63 3.73 2.25	95% CI 0.98 to 1.63 0.0 to NE 1.01 to 1.90 0.26 to 32.90 0.84 to 3.19 0.52 to 1.74 0.51 to 8.49 1.11 to 2.39 0.39 to 36.00 0.94 to 6.03	onanturumab » rirotinib	Tana Tana	placebo
Baseline Risk Factors All patients BRAF mutation Detected Not detected Obtected Great Republication Detected Obtected Ofter Great amplification Other Great amplification	No. 499 5 331 20 50 246 88 15 213 15 36 265 65 91	No. 249 3 149 12 20 120 42 7 103 7 17 128 39 46	114 1 68 1 10 58 1 9 4 46 1 7 61 2 2 4 2 1	9) Median (months)  9.1  NE 9.1  NE 6.5 7.8  NE 5.1  NE 5.1  NE 5.1  9.1  9.6  9.4	No. 250 2 162 8 30 126 46 8 110 8 19 137 26 45	(n = 25 Events 130 1 92 2 18 73 26 6 6 61 4 12 77 16 20	Median (months) 6.8 NE 6.5 12.6 5.6 6.4 8.8 4.6 6.3 5.0 3.3 6.5 6.0 8.4	1.27 > 999.99 1.39 2.92 1.42 1.34 0.95 2.08 1.63 3.73 2.25 1.33	95% CI 0.98 to 1.63 0.0 to NE 1.01 to 1.90 0.26 to 32.31 0.64 to 3.19 0.95 to 1.74 0.51 to 8.49 1.11 to 2.03 0.39 to 36.02 0.84 to 6.03 0.95 to 1.86 0.86 to 3.21 0.80 to 2.11	onanturumab » rirotinib	The state of the s	placebo
Baseline Risk Factors All patients BRAF mutation Dot dependent No call No delected No dell No delected No dell No delected MET gene amplification Amplified Dot dependent Dot defected Dot dependent Dot delected Dot del	No. 499 5 331 20 50 246 88 15 213 15 36 265 65 91 41	No. 249 3 149 12 20 120 42 7 103 7 17 128 39 46	Events  114  1 68  1 10  58  19  4  46  1 7  61  24  21	9) Median (months) 9.1 NE 9.1 NE 9.1 NE 6.5 7.8 NE 5.1 9.1 NE 5.1 9.1 NE 5.1 9.1 NE 5.1 9.1	No. 250 2 162 8 30 126 46 8 110 8 19 137 26 45	(n = 25 Events 130 1 92 18 73 26 6 6 61 4 12 77 16 20	68 NE 6.5 12.6 5.6 6.4 8.8 4.6 6.3 3.3 6.5 6.0 8.4 6.0	1.27 > 999.99 1.39 2.92 1.42 1.34 0.95 2.08 1.63 3.73 2.26 1.33 1.66 1.13	95% CI 0.98 to 1.63 0.0 to NE 1.01 to 1.30 0.26 to 32.93 0.84 to 6.18 0.52 to 1.74 0.51 to 1.89 0.39 to 1.80 0.39 to 1.80 0.84 to 6.30 0.95 to 1.86	onartuzumab » rirotinib		placebo
Baseline Risk Factors All patients 806AF mustation 806AF mustation Not detected CEGFF mustation Detected Detected Not detected Not detected Not detected Not detected Not detected Not detected PKRAS mustation Detected Detected Detected Detected Not detected NKG detected NKG detected NKG detected NKG detected NG detected Not detected Not detected CGFF great amplification Other Other	No. 499 5 331 20 50 246 88 15 213 15 36 265 65 91	No. 249 3 149 12 20 120 42 7 103 7 17 128 39 46	114 1 68 1 10 58 1 9 4 46 1 7 61 2 2 4 2 1	9) Median (months)  9.1  NE 9.1  NE 6.5 7.8  NE 5.1  NE 5.1  NE 5.1  9.1  9.6  9.4	No. 250 2 162 8 30 126 46 8 110 8 19 137 26 45	(n = 25 Events 130 1 92 2 18 73 26 6 6 61 4 12 77 16 20	Median (months) 6.8 NE 6.5 12.6 5.6 6.4 8.8 4.6 6.3 5.0 3.3 6.5 6.0 8.4	1.27 > 999.99 1.39 2.92 1.42 1.34 0.95 2.08 1.63 3.73 2.25 1.33	95% CI 0.98 to 1.63 0.0 to NE 1.01 to 1.90 0.26 to 32.31 0.64 to 3.19 0.95 to 1.74 0.51 to 8.49 1.11 to 2.03 0.39 to 36.02 0.84 to 6.03 0.95 to 1.86 0.86 to 3.21 0.80 to 2.11	onartuzumab » rirotinib		placebo
Baseline Risk Factors All patients BRAF mutation Detected Detected Detected Detected Detected Detected Detected Detected No call No call No call No detected WAS mutation Detected Detected WAS mutation Detected General mutation Detected Other General mutation Other Other MET gene amplification Other Other MET WAS MET GENERAL MUTATION OTHER MET SHA	No. 499 5 331 20 50 246 88 15 213 15 36 265 65 91 41 242	No. 249 3 149 12 20 120 42 7 103 3 7 17 128 39 46 23 116	114 1 68 1 10 58 1 19 4 4 61 7 61 24 21 11 50	9) Median (months) 9.1 NE 9.1 NE 6.5 7.8 NE 5.1 9.1 NE 9.1 1 9.6 9.4 10.1 9.4	No. 250 2 162 8 30 126 46 8 110 8 19 137 26 45 18 126	(n = 25  Events  130  1 92  2 18 73  26 61 11 277 16 20 10 65	68 Median (months) 6.8 NE 6.5 6.4 8.8 4.6 6.3 6.5 6.0 8.4 6.0 7.1	1.27 > 999.99 1.39 2.92 1.42 1.34 0.95 2.08 1.63 3.73 2.25 1.33 1.66 1.13 2.01 1.35	95% CI 0.98 to 1.63 0.0 to NE 1.01 to 1.90 0.26 to 32.93 0.64 to 3.19 0.52 to 1.74 0.51 to 1.89 0.39 to 1.74 0.39 to 1.80 0.86 to 3.21 0.86 to 3.21 0.86 to 3.21 0.86 to 3.21 0.83 to 4.87 0.93 to 1.96	onartuzumab » rirolinib		placebo
Baseline Risk Factors All patients BRAF mustation No defected EGFF mustation No defected EGFF mustation No defected No defected No defected No defected No call Detected No call No ca	No. 499 5 331 20 50 246 88 15 213 15 36 265 65 91 41 242 156	No. 249 3 149 12 20 120 42 7 7 103 7 17 128 39 46 23 116	Events  114  1 68  1 10  58  19  4  46  1 7  61  24  21	9) Median (months) 9.1 NE 9.1 NE 6.5 7.8 NE 6.5 7.8 NE 9.1 1 9.1 1 9.1 1 9.4	No. 250 2 162 8 30 126 46 8 110 8 19 137 26 45 71	(n = 25 Events 130 1 92 18 73 26 6 6 61 4 12 77 16 20	68 Median (months) 6.8 NE 6.5 12.6 5.6 6.4 8.8 4.6 6.3 5.0 3.3 6.5 6.0 8.4 6.0 7.1 6.4	1.27 > 999.99 1.39 2.92 1.42 1.34 0.95 2.08 1.63 3.73 2.25 1.33 1.66 1.13 2.01 1.35	95% CI 0.98 to 1.63 0.01 to NE 1.01 to 1.90 0.26 to 3.23 0.95 to 1.89 0.52 to 1.74 0.51 to 8.49 1.11 to 2.39 0.39 to 36.06 0.95 to 1.80 0.96 to 3.21 0.60 to 2.11 0.83 to 4.87 0.93 to 4.87 0.93 to 1.98	onartuzumab » rirolinib		placebo
Baseline Risk Factors  All patients  All patients  Baseline Risk Factors  All patients  Baseline Risk Factors  Detected  Bord Fundation  Detected  EGFF nutation  Detected  Not detected  Not detected  Not detected  FirASC mutation  Detected  Certification  Detected  FirASC mutation  Detected  FirASC mutation  Detected  Detected  Certification  Amplified  EGFF gene amplification  Amplified  EGFF gene amplification  Amplified  EGFF gene amplification  Amplified  EGFF gene amplification  MET FirST  MET FirST  MET FirST  MET Page  MET	No. 499 5 331 20 50 246 88 15 213 15 36 265 65 91 41 242	No. 249 3 149 12 20 120 42 7 103 3 7 17 128 39 46 23 116	114 1 68 1 10 58 19 4 46 17 61 24 21 11 50 45	9) Median (months) 9.1 NE 9.1 NE 6.5 7.8 NE 5.1 9.1 NE 9.1 1 9.6 9.4 10.1 9.4	No. 250 2 162 8 30 126 46 8 110 8 19 137 26 45 18 126	(n = 25  Events  130  1 92 2 18 73 26 6 61 4 12 77 16 20 10 65	68 Median (months) 6.8 NE 6.5 6.4 8.8 4.6 6.3 6.5 6.0 8.4 6.0 7.1	1.27 > 999.99 1.39 2.92 1.42 1.34 0.95 2.08 1.63 3.73 2.25 1.33 1.66 1.13 2.01 1.35	95% CI 0.98 to 1.63 0.0 to NE 1.01 to 1.90 0.26 to 32.93 0.64 to 3.19 0.52 to 1.74 0.51 to 1.89 0.39 to 1.74 0.39 to 1.80 0.86 to 3.21 0.86 to 3.21 0.86 to 3.21 0.86 to 3.21 0.83 to 4.87 0.93 to 1.96	onartuzumab » rirolinib		placebo
Baseline Risk Factors All patients BRAF mutation Not detected COFF mutation Not detected COFF mutation Detected Not detected COFF mutation Detected Not detected	No. 499 5 331 20 50 246 88 15 213 265 65 91 41 242 260 50 280 315	No. 249 3 149 12 200 120 42 7 103 7 17 128 39 46 85 150	Events 114 1 68 68 1 10 58 1 17 7 61 1 11 50 45 62	9) Median (months) 9.1 NE 9.1 NE 9.1 NE 6.5 7.8 NE 7.4 9.1 NE 7.4 9.1 9.6 9.4 10.1 9.4 9.9 9.8	No. 250 2 162 8 8 30 126 48 8 110 8 19 137 26 45 71 165 143	(n = 25  Events  130  1 92  2 18 73  26 6 6 61  4 12 77  16 20  10 65  36 87	iii) Median (months) 6.8 NE 6.5 12.6 5.6 6.4 6.3 5.0 3.4 6.5 6.0 7.1 6.4 6.9 7.0	1.27 > 999.99 1.39 2.92 1.42 1.34 0.95 2.08 1.63 3.73 2.25 1.33 1.66 1.13 2.01 1.35 1.28 1.36	95% CI 0.98 to 1.63 0.0 to NE 1.01 to 1.30 0.26 to 32.93 0.84 to 3.19 0.55 to 1.74 0.51 to 8.49 1.11 to 2.39 0.39 to 36.07 0.84 to 8.40 0.85 to 3.29 0.85 to 3.21 0.86 to 3.21 0.86 to 3.21 0.86 to 3.21 0.87 0.89 to 1.89	onarturumab + rirotinib		placebo
Baseline flisk Factors  All patients All patients BAGAF mutation Detected BAGAF mutation Detected COPP mutation No clients No call No call No call No call Amplified Other GEFF german in the call Coffer mutation Detected No call GEFF german in the	No. 499 5 331 20 50 246 888 15 213 15 38 265 65 91 41 242 156 315	No. 249 3 149 12 20 120 120 42 7 7 103 7 17 128 39 46 23 116 85 150	Events  114  1 68  1 10 58  19 4 46  1 7 61  24 21  11 50  45 62	9) Median (months) 9.1 NE 9.1 NE 9.1 NE 6.5 7.8 NE 5.1 9.1 NE 5.1 9.1 19.4 9.6 9.4 9.4 9.9	No. 250 2 162 8 30 126 46 8 110 8 19 7 137 186 126 71 165	(n = 25  Events  130  1 92  2 18 73  26 6 61  4 12 77  16 20  10 65  36 87	60) Median (months) 6.8 NE 6.5 12.6 5.6 6.4 8.8 4.6 6.3 5.0 3.3 6.5 6.0 8.4 6.0 7.1 6.4 6.9	1.27 > 999.99 1.39 2.92 1.42 1.34 0.95 2.08 1.63 3.73 2.25 1.33 1.66 1.13 2.01 1.35	95% CI  0.98 to 1.63  0.0 to NE 1.01 to 1.90  0.26 to 3.23  0.84 to 3.19 0.95 to 1.88  0.52 to 1.74  0.51 to 8.49 1.11 to 2.39  0.39 to 36.00  0.84 to 6.03  0.95 to 1.80  0.80 to 2.11  0.80 to 2.11  0.83 to 4.87  0.83 to 1.89	onarturumab + rirotinib		placebo
Baseline Risk Factors All patients BRAF mutation Not detected COFF mutation Not detected COFF mutation Detected Not detected COFF mutation Detected Not detected	No. 499 5 331 20 50 246 88 15 213 265 65 91 41 242 260 50 280 315	No. 249 3 149 12 200 120 42 7 103 7 17 128 39 46 85 150	Events 114 1 68 68 1 10 58 1 17 7 61 1 11 50 45 62	9) Median (months) 9.1 NE 9.1 NE 9.1 NE 6.5 7.8 NE 7.4 9.1 NE 7.4 9.1 9.6 9.4 10.1 9.4 9.9 9.8	No. 250 2 162 8 8 30 126 48 8 110 8 19 137 26 45 71 165 143	(n = 25  Events  130  1 92  2 18 73  26 6 6 61  4 12 77  16 20  10 65  36 87	iii) Median (months) 6.8 NE 6.5 12.6 5.6 6.4 6.3 5.0 3.4 6.5 6.0 7.1 6.4 6.9 7.0	1.27 > 999.99 1.39 2.92 1.42 1.34 0.95 2.08 1.63 3.73 2.25 1.33 1.66 1.13 2.01 1.35 1.28 1.36	95% CI  958 to 1.63 0.0 to NE 1.01 to 1.90 0.26 to 22.31 0.64 to 3.19 0.95 to 1.89 0.52 to 1.74 0.51 to 1.89 0.52 to 1.74 0.51 to 1.89 0.52 to 1.74 0.81 to 6.03 0.95 to 1.86 0.89 to 3.07 0.84 to 6.03 0.95 to 1.86 0.89 to 3.07 0.84 to 6.03 0.95 to 1.86 0.86 to 2.21 0.80 to 2.11	onatruzumab + rirotinib		placebo
Baseline Risk Factors All patients BRAF mutation Not detected COFF mutation Not detected COFF mutation Detected Not detected COFF mutation Detected Not detected	No. 499 5 331 20 50 246 88 15 213 265 65 91 41 242 260 50 280 315	No. 249 3 149 12 200 120 42 7 103 7 17 128 39 46 85 150	Events 114 1 68 68 1 10 58 1 17 7 61 1 11 50 45 62	9) Median (months) 9.1 NE 9.1 NE 9.1 NE 6.5 7.8 NE 7.4 9.1 NE 7.4 9.1 9.6 9.4 10.1 9.4 9.9 9.8	No. 250 2 162 8 8 30 126 48 8 110 8 19 137 26 45 71 165 143	(n = 25  Events  130  1 92  2 18 73  26 6 6 61  4 12 77  16 20  10 65  36 87	iii) Median (months) 6.8 NE 6.5 12.6 5.6 6.4 6.3 5.0 3.4 6.5 6.0 7.1 6.4 6.9 7.0	1.27 > 999.99 1.39 2.92 1.42 1.34 0.95 2.08 1.63 3.73 2.25 1.33 1.66 1.13 2.01 1.35 1.28 1.36	95% CI  0.98 to 1.63  0.0 to NE 1.01 to 1.90 0.26 to 32.93 0.84 to 3.19 0.55 to 1.89 0.52 to 1.79 0.51 to 1.89 0.39 to 1.80 0.39 to 36.03 0.84 to 6.03 0.85 to 1.86 0.86 to 3.21 0.83 to 4.87 0.93 to 1.86	onatruzumab + rirotinib		placebo

Fig 4. Subanalyses of (A) progression-free and (B) overall survival in biomarker subgroups. EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization; HR, hazard ratio; NE, not evaluable.